STOCK TITAN

Jaguar Health, Inc. - JAGX STOCK NEWS

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.

Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.

In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).

Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.

Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.

Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.

For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.

Rhea-AI Summary

Jaguar Health has signed an exclusive license and service agreement with SynWorld Technologies to market Canalevia for treating diarrhea in dogs in China. The agreement includes $5 million in license fees and $5 million in stock purchases over two years. Jaguar is set to receive 60% of profits from sales, increasing to 80% if they cover regulatory costs. The Chinese pet market is projected to reach $70.5 billion by 2023. This agreement aligns with Jaguar's goals for expanding Canalevia's availability and supporting its human pipeline development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced the online availability of a presentation by Dr. Mohamad Miqdady on Short Bowel Syndrome (SBS) from the Elite Ped-GI Congress in Abu Dhabi, held from May 19-21, 2022. The presentation emphasizes the severe impacts of SBS and congenital diarrheal disorders (CDD), for which current treatment options are limited. The company’s subsidiary, Napo Therapeutics, received orphan-drug designations in the EU and the US for crofelemer, offering hope for patients. The congress aims to update healthcare professionals on pediatric gastroenterology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced its participation in the ACVIM Forum from June 23-25, 2022, in Austin, TX, to promote Canalevia-CA1, its FDA-conditionally approved treatment for chemotherapy-induced diarrhea in dogs. This product is crucial as many veterinarians report CID impacts chemotherapy plans, highlighting an unmet need. Canalevia-CA1 is derived from the Croton lechleri tree and offers a novel treatment option for affected dogs. The product is available through major veterinary distributors, supporting its commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced the publication of an article on June 8, 2022, highlighting the critical need for managing diarrhea in cancer patients, which can affect 50% to 100% of patients undergoing treatment. The article underscores that uncontrolled diarrhea can lead to significant health issues and impact patient quality of life. Jaguar's crofelemer product is in a pivotal Phase 3 trial for preventing diarrhea in adults, while its Canalevia-CA1 for dogs has conditional FDA approval. The company emphasizes the urgency of addressing this side effect for improved treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.02%
Tags
none
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all four proposals at its 2022 Annual Meeting of Stockholders held on June 10, 2022. The details of the proposals are available in the definitive proxy statement filed with the SEC. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues, including Mytesi®, which is specifically for noninfectious diarrhea in HIV/AIDS patients. The company aims to expand access to its products in Europe through its subsidiary Napo Therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.02%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced its participation in BIO 2022, scheduled for June 13-16, 2022, in San Diego. Karen Brunke, PhD, EVP of Corporate Development, will engage in one-on-one meetings to seek partnerships related to crofelemer, an FDA-approved treatment for diarrhea in adults with HIV/AIDS. The company aims to explore further applications for cancer therapy-related diarrhea and inflammatory bowel disease. Additionally, Jaguar is pursuing collaborations to advance its extensive library of medicinal plants and recently collaborated with Filament Health for developing botanical prescription drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
conferences
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Therapeutics, has submitted an Orphan Drug Designation application for crofelemer to the European Medicines Agency (EMA) for microvillus inclusion disease (MVID), a severe congenital diarrheal disorder. This submission marks a significant step towards addressing the unmet medical need for MVID, which can cause severe complications in newborns and children. If granted, the designation offers regulatory benefits, including a 10-year market exclusivity upon approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) presented a study on crofelemer as a potential treatment for Microvillus Inclusion Disease (MVID), a severe congenital diarrheal disorder, at Digestive Disease Week 2022. The study, led by Dr. Jay Thiagarajah, demonstrates crofelemer's potential for managing symptoms and electrolyte balance in MVID patients. This research supports Napo Therapeutics' application for Orphan Drug Designation from the European Medicines Agency. Crofelemer holds ODD for short bowel syndrome in both the EU and US.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
none
-
Rhea-AI Summary

Jaguar Health launched Take C.H.A.R.G.E., a national registry addressing canine cancer, which coincides with National Canine Cancer Awareness Day on May 23, 2022. Initial data from a Gallup Poll of over 3,500 dog owners reveal a 2.8% incidence of canine cancer—five times greater than humans. Over 80% of respondents advocate for a registry to better understand the disease. The registry aims to gather data from 35,000 canine medical records to enhance diagnosis and treatment, highlighting the need for improved canine healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Rhea-AI Summary

Jaguar Health is hosting a media event in NYC on May 23, 2022, to launch the Canine Cancer: Take C.H.A.R.G.E. initiative, the first U.S. Canine Cancer Registry. This registry will assess cancer prevalence in dogs by analyzing anonymized medical records and survey data. The event coincides with the inaugural National Canine Cancer Awareness Day and features veterinary cancer specialists and Broadway performances. The initiative aims to improve understanding of canine cancer, benefiting both pets and potentially human health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $1.11 as of September 19, 2024.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 10.4M.

What is Jaguar Health, Inc.?

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company developing novel, plant-based prescription medicines for gastrointestinal distress in humans and animals.

What are the main products of Jaguar Health?

Jaguar Health's main products include Mytesi® for noninfectious diarrhea in adults with HIV/AIDS, Canalevia™ for treating diarrhea in dogs, and Equilevia™ for equine gut health. They are also developing Gelclair® for oral mucositis.

What is Mytesi® used for?

Mytesi® (crofelemer) is an antidiarrheal medication approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

What is the OnTarget study?

The OnTarget study is a Phase 3 clinical trial evaluating the effectiveness of crofelemer in preventing chemotherapy-induced overactive bowel (CIOB) in adults undergoing cancer therapy.

What recent achievements has Jaguar Health made?

Recent achievements include the approval of crofelemer as an Orphan Drug for SBS and MVID, initiation of phase 2 clinical trials in Europe, and preparation for the commercial launch of Gelclair®.

What is the focus of Magdalena Biosciences?

Magdalena Biosciences, a joint venture with Filament Health Corp., focuses on developing novel plant-based prescription medicines for mental health indications, including a botanical drug candidate for schizophrenia.

What are the financial highlights for Jaguar Health in Q1 2024?

In Q1 2024, Jaguar Health reported a combined net revenue of approximately $2.4 million, a 20% increase compared to Q1 2023. The company continues to invest in R&D, particularly for rare disease treatments.

What sustainability practices does Jaguar Health follow?

Jaguar Health employs sustainable harvesting practices under fair trade guidelines for the plant-based ingredients used in their products, ensuring high quality and ecological integrity.

How can I stay updated on Jaguar Health's developments?

You can stay updated by visiting Jaguar Health's official website, and following them on LinkedIn, X (formerly Twitter), and Instagram.

What is Gelclair® and its use?

Gelclair® is an FDA-approved prescription product used for managing and relieving pain associated with oral mucositis, a common side effect of cancer treatments.

Jaguar Health, Inc.

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

10.44M
9.24M
11.64%
1.14%
7.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO